Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Delta
Omicron
SARS-CoV-2
convalescent
long-term
microneutralization
neutralization
neutralizing antibodies
vaccine
variants of concern
Journal
Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215
Informations de publication
Date de publication:
10 06 2022
10 06 2022
Historique:
received:
08
02
2022
revised:
21
03
2022
accepted:
06
04
2022
pubmed:
20
4
2022
medline:
15
6
2022
entrez:
19
4
2022
Statut:
ppublish
Résumé
SARS-CoV-2 Omicron variant of concern (VOC) has evolved multiple mutations within the spike protein, raising concerns of increased antibody evasion. In this study, we assessed the neutralization potential of COVID-19 convalescent sera and sera from vaccinated individuals against ancestral SARS-CoV-2 and VOCs. The neutralizing activity of sera from 65 coronavirus disease (COVID-19) vaccine recipients and convalescent individuals against clinical isolates of ancestral SARS-CoV-2 and Beta, Delta, and Omicron VOCs was assessed using a micro-neutralization assay. Convalescent sera from unvaccinated individuals infected by the ancestral virus demonstrated reduced neutralization against Beta and Omicron VOCs. Sera from individuals that received three doses of the Pfizer or Moderna vaccines demonstrated reduced neutralization of the Omicron variant relative to ancestral SARS-CoV-2. Sera from individuals that were naturally infected with ancestral SARS-CoV-2 and subsequently received two doses of the Pfizer vaccine induced significantly higher neutralizing antibody levels against ancestral virus and all VOCs. Infection alone, either with ancestral SARS-CoV-2 or the Delta variant, was not sufficient to induce high neutralizing antibody titers against Omicron. In summary, we demonstrate that convalescent and vaccinated sera display varying levels of SARS-CoV-2 VOC neutralization. Data from this study will inform booster vaccination strategies against SARS-CoV-2 VOCs. This research was funded by the Canadian Institutes of Health Research (CIHR). VIDO receives operational funding from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture and from the Canada Foundation for Innovation through the Major Science Initiatives for its CL3 facility.
Sections du résumé
Background
SARS-CoV-2 Omicron variant of concern (VOC) has evolved multiple mutations within the spike protein, raising concerns of increased antibody evasion. In this study, we assessed the neutralization potential of COVID-19 convalescent sera and sera from vaccinated individuals against ancestral SARS-CoV-2 and VOCs.
Methods
The neutralizing activity of sera from 65 coronavirus disease (COVID-19) vaccine recipients and convalescent individuals against clinical isolates of ancestral SARS-CoV-2 and Beta, Delta, and Omicron VOCs was assessed using a micro-neutralization assay.
Findings
Convalescent sera from unvaccinated individuals infected by the ancestral virus demonstrated reduced neutralization against Beta and Omicron VOCs. Sera from individuals that received three doses of the Pfizer or Moderna vaccines demonstrated reduced neutralization of the Omicron variant relative to ancestral SARS-CoV-2. Sera from individuals that were naturally infected with ancestral SARS-CoV-2 and subsequently received two doses of the Pfizer vaccine induced significantly higher neutralizing antibody levels against ancestral virus and all VOCs. Infection alone, either with ancestral SARS-CoV-2 or the Delta variant, was not sufficient to induce high neutralizing antibody titers against Omicron.
Conclusions
In summary, we demonstrate that convalescent and vaccinated sera display varying levels of SARS-CoV-2 VOC neutralization. Data from this study will inform booster vaccination strategies against SARS-CoV-2 VOCs.
Funding
This research was funded by the Canadian Institutes of Health Research (CIHR). VIDO receives operational funding from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture and from the Canada Foundation for Innovation through the Major Science Initiatives for its CL3 facility.
Identifiants
pubmed: 35437520
doi: 10.1016/j.medj.2022.04.002
pii: S2666-6340(22)00168-4
pmc: PMC9008123
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Membrane Glycoproteins
0
Spike Glycoprotein, Coronavirus
0
Viral Envelope Proteins
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
422-432.e3Subventions
Organisme : CIHR
ID : OV5-170349
Pays : Canada
Organisme : CIHR
ID : VRI-173022
Pays : Canada
Organisme : CIHR
ID : VS1-175531
Pays : Canada
Organisme : CIHR
ID : 439999
Pays : Canada
Organisme : CIHR
ID : 465038
Pays : Canada
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
S.W. has served on advisory boards, speaking engagements, attended meetings and symposiums, and conducted clinical studies for ViiV Health Care, GSK, Merck, Janssen, and Gilead Sciences outside of the submitted work. A.J.M. reports income from advisory board membership from Astra-Zeneca, GlaxoSmithKline, Janssen, Medicago, Merck, Moderna, Pfizer, and Sanofi-Pasteur, and research grant funds paid to her institution from Pfizer and Sanofi-Pasteur.